AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05566626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperspectral retinal image
Description: Hyperspectral image of both eyes
Study NCT05566626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mydriacyl Ophthalmic Product
Description: Mydriatic drops before retinoscopy
Study NCT05746676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: in treatment of periodontal defects
Study NCT05746676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: in treatment of periodontal defects
Study NCT05793827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Hatha Yoga
Description: Yoga includes breath work (pranayama), gentle stretching and holding of postures (asanas), and meditation (dhyana). Modifications/adaptations are incorporated so all participants can successfully complete the yoga intervention. Yoga is delivered in a standardized progression, including: focused, slow breath with movement and breathwork throughout every session; mantras, progressively challenging yoga postures (sitting, standing, and floor); and meditation
Study NCT05793827 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Impact Exercise
Description: This includes low-intensity exercise, which is matched to the estimated metabolic costs of yoga, 2.5 Metabolic Equivalent of Task (MET). Sessions include warm up, cool down, and five, 10-minute exercise stations, (e.g., walking, balance, resistance bands, weight-bearing exercise, and core work). Control exercise will be prescribed between 2.0 to 3.0 METs, equating to 30 to 40% heart rate reserve. Heart rate zones are calculated for each participant and monitored to ensure proper intensity
Study NCT06418360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional physical therapy; Transcutaneous Electrical Nerve Stimulation, hotpack
Description: 10 sessions of HP and TENS for two weeks, five times a week. HP was applied to the painful knee area for 20 minutes using a heating pad for superficial heating purposes. TENS was applied to the painful knee area for 20 minutes at 80 Hz frequency
Study NCT06257186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: Participants assigned to the Intervention (Art Therapy) arm will be offered a series of three to five art therapy sessions, depending on the participants' needs/preferences. The art therapy sessions will be given anytime after consent has been obtained till approximately 36 weeks of gestation. The Art Therapy is given in addition to routine antenatal care.
Study NCT00705796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPP10, testosterone
Description: Testosterone intranasal, 7.6 mg, twice daily to be taken immediately after waking up and washing/showering (approx. 7:00-8:00 AM) and at lunch time (approx. 12:00 AM).
Study NCT00705796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: AndroGel® 50 mg, once daily in the morning after washing/showering.
Study NCT05797857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: A supervised, personalized exercise training program, which will consist of two 60-minute exercise training sessions per week.
Study NCT06232759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab
Description: Patients with unresectable hepatocellular carcinoma were received transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab
Study NCT04954209 — intervention group
Intervention type: OTHER
Intervention: Physical activities in hospital
Description: 3 month in a resumption program of physical activity in hospital
Study NCT04954209 — intervention group
Intervention type: OTHER
Intervention: Physical activity outside hospital
Description: 3 month in a resumption program of physical activity outside hospital with discovery sessions
Study NCT05020860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab/Trastuzumab/Hyaluronidase-zzxf
Description: Can be used in place of separate IV formulations of pertuzumab and trastuzumab. 1200 mg pertuzumab/600 mg trastuzumab/30,000 U hyaluronidase administered subcutaneously on Day 1 of the first cycle, followed by a maintenance dose of 600 mg pertuzumab/600 mg trastuzumab/20,000 U hyaluronidase administered subcutaneously every 3 weeks.
Study NCT05224518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: elastic band training
Description: elastic band training include stretching exercises
Study NCT05224518 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: elastic band training
Description: elastic band training include stretching exercises
Study NCT06476301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: To compare the efficacy and safety of rivaroxaban as an early anticoagulant therapy for BPV patients with the traditional postoperative anticoagulant warfarin
Study NCT06475547 — intervention group
Intervention type: OTHER
Intervention: Descriptive
Description: This study is observational and does not involve any clinical intervention. The primary procedure involves the collection of epicardial fat tissue samples. The collected samples are then processed and analyzed to compare inflammatory gene expression between the two groups. The analysis includes RNA sequencing to identify differentially expressed genes associated with atrial fibrillation and inflammation.
Study NCT04816734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-report questionnaires
Description: Evaluation system of initial therapeutic education program about pediatric home parenteral nutrition.~The assessment takes place after the parents have participated in the therapeutic education program and before their child returns home.
Study NCT06578754 — intervention group
Intervention type: OTHER
Intervention: This is an non-interventional study
Description: Only blood samples will be required in this study. It is noninterventional.
Study NCT04690322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eloctate
Description: Eloctate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.
Study NCT04690322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adynovate
Description: Adynovate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.
Study NCT04690322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emicizumab
Description: Emicizumab is FDA-approved to treat patients with Hemophilia A. This drug will be used for non-factor VIII-based replacement therapy.
Study NCT06390423 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Passive leg raise, SVI via bioreactance, Echo based VTI
Description: No interventions other than fluid challenge
Study NCT05627388 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dreem 3 System At-Home Monitoring
Description: Patients will be asked to wear the Dreem 3 System and actigraphy devices at home. Research support staff will teach patients how set up the device beforehand. Patients will wear Dreem and actigraph for 5 nights, while keeping the actigraph on during the day, to monitor sleep/wake cycle. Then, for an additional continuous 48hr measurement, patients will wear the Dreem and actigraph. The patient will be given 2 devices, as one device can record up to 24h of data continuously. Patients are not required to stay home during the 48hr testing period. However, patients will be instructed to refrain from participating in activities which may shift or require removal of Dreem. Patients who wish to remain home for the 48hr testing period should have adequate sustenance (i.e., groceries). Any caffeine and sleep medication intake will be logged by the patient in a sleep diary. If needed, patients will be given an off work order from work/school for the 48hr assessment.
Study NCT05139901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dornase Alfa
Description: inhalations twice daily
Study NCT05139901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: inhalations twice daily
Study NCT05096026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard PCP Outreach
Description: These patients were sent two study outreach messages. Study Outreach 1 was an electronic secure message sent on behalf of the PCP, encouraging COVID-19 vaccination and designed based on behavioral science principles. Letters were sent to patients who had not signed up for the electronic health record portal. Study Outreach 2 was a postcard sent to all patients who had not been vaccinated or made an appointment by four weeks after Study Outreach 1.
Study NCT05096026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Tailored PCP Outreach
Description: These patients were sent messages similar to those in Standard PCP Outreach, but with additional culturally tailored content and photos.
Study NCT05632809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-255
Description: Given by IV (vein)
Study NCT05632809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given by IV (vein)
Study NCT05724576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OmniMSC-AMI
Description: 10 anterior wall STEMI patients without cardiogenic shock will be enrolled into low dose group 1 (1.5 x 10\^7 OmniMSC-AMI, n=5) and then high dose group 2 (3.0 x 10\^7 OmniMSC-AMI, n=5).
Study NCT04793412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implant
Description: Cochlear implantation of a device from one of the three manufacturers available in the US.
Study NCT04318249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assisted Relaxation Therapy
Description: This intervention includes using a smartphone application that helps with breathing techniques and sleep.
Study NCT04318249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Assisted Relaxation Therapy
Description: This intervention includes using a smartphone application that is modified to help with breathing techniques and additional sleep instructions.
Study NCT06328543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histamine
Description: Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine.
Study NCT04672577 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: No intervention is planned
Study NCT04801303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Administration of Calcitrol 0.25mcg/24h for a year in Friedreich's Ataxia patients (n=20)
Study NCT04801303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood analysis for frataxin's level measurement
Description: 1. Five blood analysis in Friedreich's Ataxia patients: before starting the treatment, and after fifteen days, 4 months, 8 months and 12 months of the treatment.~2. To validate the Frataxin's levels measurement, a blood analysis will also be done in two kind of controls for every Friedreich's Ataxia patient, only once at the beginning of the trial.~The control groups will be composed by:~* Heterozygous Ataxia's Friedreich controls (a close relative of the patient, either a heterozygous sibling or one of the parents)~* Age- and gender-matched controls (supposedly non-heterozygous).
Study NCT04801303 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood analysis for hypercalcemia's control
Description: Five blood analysis in Friedreich's Ataxia patients for monitoring the hypercalcemia risk (with measurement of Calcium, D Vitamin, renal function, albumin, protein, phosphate, sodium and potassium) Before starting the treatment, and after fifteen days, at 4 months, 8 months and 12 months of the treatment.
Study NCT06328543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: 25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
Study NCT05488743 — intervention group
Intervention type: BEHAVIORAL
Intervention: educational intervention
Description: The program consists of five 50-minutes sessions conducted in person as scheduled during weekly class meetings. Educators will conduct workshops with PowerPoint presentations and worksheets dedicated to in-class activities.
Study NCT04760977 — intervention group
Intervention type: DRUG
Intervention: Drugs administration
Description: Antifibrinolytics, analgesics, sedatives, neuromuscular blocking agents
Study NCT04760977 — intervention group
Intervention type: DEVICE
Intervention: Resuscitative endovascular balloon occlusion of the aorta
Description: Resuscitative technique for exsanguinating traumas
Study NCT04760977 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood transfusions
Description: Transfuion of transported blood products for exsanguinating traumas
Study NCT04760977 — intervention group
Intervention type: OTHER
Intervention: Prehospital management
Description: Stay and play strategy vs scoop and run
Study NCT04760977 — intervention group
Intervention type: DEVICE
Intervention: Prehospital eFAST
Description: Prehospital thorax/abdomen extended focused assessment sonography for trauma
Study NCT05273528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine
Description: The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
Study NCT04584801 — intervention group
Intervention type: DEVICE
Intervention: Structured Light Plethysmography
Description: Development Phase (Original Part A): Participants will have two 5-minute SLP measurements (Pre and Post bronchodilator).~Participants will also undergo standard of care spirometry assessment
Study NCT06353464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ensure and Water
Description: Ensure, a liquid meal with 9 grams of protein in 8 ounces consumed 20 minutes before eating pizza; and water, 8 ounces consumed 20 minutes before eating pizza
Study NCT06068062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modification of OSCE using TBL format
Description: Modification of Team-based learning format and implementing OSCE using that modified format to teach clinical skills to medical students.To teach clinical skills this structure of TBL was modified and with use of OSCE following strategy was planned as intervention. First of all, the students were provided with the resource material regarding the skills to be taught. Then a formative OSCE session was organized where students were divided into groups each with 5 students. They were rotated in two OSCE stations. First each student one by one was supposed to perform the task that was clearly documented and was evaluated by peers and facilitator. Immediate feedback from peers and facilitators was given to each student. Students were also instructed to discuss among themselves and designate roles also to make a plan and act like team in performing task on OSCE station 2.
Study NCT05538286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearFit implant
Description: The ClearFit implant is an FDA cleared implant in regular use in the United States. The ClearFit implant and other PMMA cranioplasty implants manufactured by Longeviti have been reported to be safe and effective as cranial implants that permit transcranial ultrasound to be performed. The PMMA cranioplasty implant (Longeviti Neuro Solutions, Hunt Valley, MD) is clear, sonolucent, and was recently shown to be safe and effective in transcranial ultrasonography for bypass patency assessment. The ClearFit cranioplasty being used in this study is industry standard of care.
Study NCT05538286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial ultrasonography through sonolucent cranioplasty
Description: The implantation of the ClearFit PMMA sonolucent implant permits TUSC to be performed at the bedside for patients in both the in-patient and outpatient settings. While the patient is an inpatient, the clinical or research teams will attempt to perform TUSC within 1 hour of neuroimaging if that neuroimaging is performed at a time when a trained ultrasound operator is present.
Study NCT05151172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endovascular thrombectomy (EVT)
Description: minimally invasive endovascular surgery for mechanical removal of occluding intracranial thrombus
Study NCT05151172 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standarad medical care
Description: Stanadard medical care wil involve use of thrombolytic drugs, Blood pressure management, use of antiplatelet or anti coagulant drugs
Study NCT05652686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT217
Description: A bispecific antibody (bsAb) against DLL3 and CD47.
Study NCT05652686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin + Etoposide
Description: Administered per Standard of Care.
Study NCT05652686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel.
Description: Administered per Standard of Care.
Study NCT05652686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Administered per Standard of Care.
Study NCT06567964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block(ESPB)
Description: ESPB was administered preoperatively under ultrasound guidance via a high-frequency linear probe (Sonosite M-Turbo, Fujifilm Sonosite Inc., USA) (Figure 1). The procedure was as follows:~1. Patient Positioning: The patient was positioned in the lateral decubitus position, with the side to be blocked uppermost.~2. Ultrasound Setup: A high-frequency linear ultrasound probe was placed in a parasagittal orientation over the transverse process of the lumbar vertebra at the level of surgery.~3. Needle Insertion: After skin disinfection with chlorhexidine, a 22-gauge, 100-mm needle (Stimuplex A, B. Braun Melsungen AG, Germany) was inserted in-plane to the ultrasound probe. The needle was advanced until the tip contacted the transverse process.~4. Injection: Following negative aspiration to ensure no vascular puncture, 20 mL of 0.5% bupivacaine was injected incrementally, with real-time ultrasound visualization to confirm the correct spread of the anesthetic solution.
Study NCT06567964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration
Description: Wound infiltration was performed by the surgeon at the end of the surgery via the following procedure:~1. Preparation: After hemostasis was achieved and before skin closure, 20 mL of 0.5% bupivacaine was prepared in a sterile syringe.~2. For infiltration, the anesthetic mixture was infiltrated into multiple layers of the surgical wound. This included the subcutaneous tissue and muscle layers, ensuring the even distribution of the anesthetic solution to cover the entire surgical area.
Study NCT05636501 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treat-to-target Prednisolone Taper
Description: Systematic prednisolone taper
Study NCT05636501 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Prednisolone taper performed by discretion of the patient's general practitioner.
Study NCT04831021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis without physical exercise
Description: Hemodialysis control condition
Study NCT04831021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis with pre-dialytic physical exercise
Description: Patients will pedal for 30 minutes using a ergometer directly attached to the dialysis bed. The exercise will be performed 60 minutes before connection to hemodialysis.
Study NCT04831021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis with per-dialytic physical exercise
Description: Patients will pedal for 30 minutes using a ergometer directly attached to the dialysis bed. The exercise will start 30 minutes after the start of dialysis.
Study NCT06114381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Based Physical Exercise
Description: Home Exercise protocol consists of one hour divided to 3 minutes warm up,9 minutes' full body (lower limbs, abdomen, back and upper limbs) exercise composed of (aerobic and strengthening) and 3 minutes cool down 4 times per day and 15 minutes for each session 6 days with one day recovery and, with every day follow up with each patient to ensure they did the whole sets and instructed them the ways to each exercise, The total duration was 36 sessions (6 weeks) for each patient. Daily communication with all subjects through sending mobile messages 3 times every day. The message was to remind the participants and confirmation of their response.
Study NCT06114381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 Supplements
Description: Vitamin D3 supplement (400mg) once daily.
Study NCT06114381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Management
Description: Patients receive weekly diet program contains dietary sources of Vitamin D such as yolk eggs, tuna and milk.
Study NCT06114381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sun Exposure
Description: Patients regular exposure to sun once a day 30 minutes of sun exposure, between 10 a.m. and 4 p.m. daily. Exposure to the face, arms, hands, and legs without sunscreen
Study NCT05339373 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aceclofenac film-coated tablet 100 mg
Description: Aceclofenac is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 100 mg of aceclofenac.
Study NCT05339373 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Airtal® film-coated tablet 100 mg
Description: Airtal ® is manufactured by Gedeon Richter- RUS, Russia / Gedeon Richter, Hungary. Each tablet contains 100 mg of aceclofenac.